Solu Therapeutics is at the forefront of developing a novel therapeutic platform that combines small molecules with effector antibodies to target cell surface proteins that are typically inaccessible through conventional methods. Their proprietary technology utilizes bifunctional small molecules, which consist of two arms: one that engages extracellular targets and another that connects to proprietary antibodies via a unique linker technology. This innovative approach allows for the creation of a new class of drugs that leverage the pharmacokinetic properties of antibodies while enhancing the specificity and efficacy of treatment. The platform is designed to address high-value drug discovery targets, particularly in oncology and immunology, by enabling the targeted elimination of pathogenic cells and the modulation of immune responses.

The company has developed two primary platforms: the CyTAC (Cytotoxicity Targeting Chimera) and the TicTAC (Therapeutic Index Control Targeting Chimera). The CyTAC platform focuses on linking small molecules to antibodies to selectively target and eliminate tumor cells and pathogenic immune cells, thereby addressing unmet needs in cancer and inflammatory diseases. Meanwhile, the TicTAC platform aims to enhance the pharmacokinetic profiles of small molecule agonists and antagonists, providing long-acting therapeutic options across various indications. By advancing these platforms, Solu Therapeutics is positioned to transform patient care through the development of innovative medicines that were previously deemed impossible.

United States

Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate cells that drive oncologic, inflammatory, and autoimmune diseases.

Solu Therapeutics

Company Details